New Triple-Drug attack on tough endometrial cancer begins testing
NCT ID NCT07318324
Summary
This early-phase study aims to find a safe and effective dose of a three-drug combination (avutometinib, defactinib, and everolimus) for people with recurrent endometrial cancer that has specific genetic changes in the RAS pathway. It will enroll about 31 participants who have already tried other treatments, including immunotherapy. The main goals are to determine the best dose for future studies and to closely monitor the safety and side effects of this new combination.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.